Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Acute vulvovaginal candidiasis is a fungal/yeast infection, which is caused by some species of Candida, especially Candida albicans. Increasing cases of vulvovaginal candidiasis can be attributed to ageing, overuse of antibiotics, diabetes, etc. Doctors are involved in prescribing medicines on the basis of their efficiency in controlling acute vulvovaginal candidiasis among the patients. For instance, according to National Center for Biotechnology Information (NCBI): 2018, clotrimazole, nystatin, and fluconazole are the most commonly prescribed drugs for the treatment of acute vulvovaginal candidiasis. Apart from these drugs, other drugs such as Miconazole, Ketoconazole, Terbinafine, Terconazole, and others are also available in the market.

Global Acute Vulvovaginal Candidiasis Treatment Market - Impact of the Coronavirus (COVID-19) Pandemic

COVID-19 pandemic is expected to hamper growth of the global acute vulvovaginal candidiasis treatment market during the forecast period. According to the Indian Journal of Medical Sciences, June 6, 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to unavailability of trial site staff, restrictions for travelling, investigational product availability, and others. These challenges are hindrances for developing new treatment for acute vulvovaginal candidiasis.

Incidence of candidiasis among the patients in the intensive care unit is increasing. For instance, according to the MDPI, Journal of Fungi: September 11, 2020, candidiasis (oropharyngeal candidiasis or vulvovaginitis candidiasis, invasive candidiasis, and others) is one of the reasons for causing mortality in 19 – 40% of patients in the ICU. The COVID-19 positive patients are usually treated in the ICU, and the recovery rate may be affected due to the occurrence of candidiasis in such patients.

The global acute vulvovaginal candidiasis treatment is estimated to be valued at US$ 308.0 Mn in 2020 and is expected to exhibit a CAGR of 3.0% over the forecast period (2020-2027).

Figure 1: Global Acute Vulvovaginal Candidiasis Treatment Market Share (%) Analysis, By Drug Type, 2020

Acute Vulvovaginal Candidiasis Treatment  | Coherent Market Insights

Increasing prevalence of acute vulvovaginal candidiasis is expected to drive growth of the global acute vulvovaginal candidiasis treatment market over the forecast period

Increasing incidence of acute vulvovaginal candidiasis among the population is expected to drive growth of the global market over the forecast period. For instance, according to the article published in the Lancet Journal, Infectious diseases segment: 2018, globally, approximately 138 million women suffer from recurrent vulvovaginal candidiasis (relapse of acute vulvovaginal candidiasis, at least three times, within twelve months) and 3,871 per 100,000 women suffer from vulvovaginal candidiasis every year. According to the same source, it is also estimated that by 2030, 158 million women are expected to be affected by vulvovaginal candidiasis.

Increasing product launches for the treatment of vulvovaginal candidiasis is expected to drive growth of the acute vulvovaginal candidiasis treatment market over the forecast period

Market players are engaged in launching new products for the treatment of vulvovaginal candidiasis, which is expected to drive growth of the acute vulvovaginal candidiasis treatment market over the forecast period. For instance, on July 16, 2020, Cadila Pharmaceuticals launched Fenticonazole Nitrate Vaginal Capsules under the brand name, Fenticad,(600 mg), for the treatment of vulvovaginal candidiasis. The Fenticad capsules are 35% cost-effective as compared to the already available capsules in the market.

request-sample

Acute Vulvovaginal Candidiasis Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 308 Million
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 3.0 % 2027 Value Projection: US$ 397.8 Million
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others.
  • By Route of Administration: Oral, Intravenous, Topical.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.

Growth Drivers:
  • Increasing prevalence of acute vulvovaginal candidiasis
  • Increasing number of product launches
Restraints & Challenges:
  • Increasing resistance against antifungal drugs
  • Incidence of miscarriage due to fluconazole

Global Acute Vulvovaginal Candidiasis Treatment Market – Restraints

Increasing resistance for antifungal drugs among the population is one of the factors that is expected to restrain growth of the market. For instance, according to the National Center for Biotechnology Information (NCBI), 2017, the resistance due to fluconazole, an antifungal drug, may differ upon the type of infection caused by the Candida species. Moreover, in Asia Pacific, the fluconazole resistance for different Candida species ranges from 0% to 83%.

Furthermore, increasing exposure of fluconazole during pregnancy increases the chances of abortions and still births. For instance, according to the article published in NCBI: 2019, fluconazole was tested on 441,949 pregnant women, out of which 320,868 pregnancies had spontaneous abortions, 226,599 pregnancies had major congenital malformations, and 7,832 pregnancies resulted in still births. The above factor is expected to restrain the global acute vulvovaginal candidiasis treatment market growth over the forecast period.

Global Acute Vulvovaginal Candidiasis Treatment Market – Regional Analysis

North America is expected to hold dominant position in the global acute vulvovaginal candidiasis treatment market over the forecast period, owing to the provision of reimbursement policy for the diagnosis and testing of vaginal fungal infection. For instance, according to the Blue Cross Blue Shield Association, a federation of 36 U.S. health insurance companies, it provides reimbursement policy for the diagnosis of vulvovaginal candidiasis in patients who show symptoms of the infection. The reimbursement is also provided for the patients who receive negative results for the tests conducted.

Moreover, Europe is also an emerging region for the acute vulvovaginal candidiasis treatment market, owing to the increasing prevalence of vaginal fungal infections among the population. For instance, according to the article published in National Center for Biotechnology Information (NCBI), 2019, in Sweden, it has been estimated that 17% of the total population suffer from fungal infections. Moreover, out of the total population, 49.8% constitutes female population. In the study, it was prevalent that the recurrent vulvovaginal candidiasis is very common and out of the total female population, 6% of the females suffer from recurrent vulvovaginal candidiasis.

Figure 2: Global Acute Vulvovaginal Candidiasis Treatment Market (US$ Mn), by Region, 2020

Acute Vulvovaginal Candidiasis Treatment  | Coherent Market Insights

Global Acute Vulvovaginal Candidiasis Treatment Market – Competitive Landscape

Major players operating in the global acute vulvovaginal candidiasis treatment market include Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.

Acute vulvovaginal candidiasis is a yeast infection, which affects the vagina and tissues present at the opening of the vulva. It is caused by fungus Candida species. The symptoms for the infection are intense itchiness, inflammation, thick, white discharge, and others. Mild infection can be cured with a single dose of the antifungal agent or by application of antifungal creams while severe infections require longer treatment.

Market Dynamics

Market players are indulged in inorganic activities such as acquisition, which is expected to expand their product portfolio and strengthen their position in the global market, and drive growth of the global market over the forecast period. For instance, on June 7, 2020, ANI Pharmaceuticals Inc. acquired Fluconazole Tablets (50mg, 100mg, 150mg, and 200mg) from a private company for US$ 3 million. Thus, ANI Pharmaceuticals expanded their product portfolio by including drugs for the treatment of acute vulvovaginal candidiasis.

Increasing research and development for developing treatment for vulvovaginal candidiasis is expected to drive growth of the global acute vulvovaginal candidiasis treatment market over the forecast period. For instance, according to the article published in the BMC Microbiology Journal: 2018, Nystatin, an oral medication for the treatment of vulvovaginal candidiasis, when used in the vaginal epithelial cells (VEC) infected with Candidiasis albicans, increased the levels of IFN-γ, IL-17, and IgG in the cells as compared to the uninfected cells. Therefore, Nystatin upregulates the host defense mechanism against Candida albicans.

Key features of the study:

  • This report provides an in-depth analysis of global acute vulvovaginal candidiasis treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020 – 2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global acute vulvovaginal candidiasis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global acute vulvovaginal candidiasis treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the acute vulvovaginal candidiasis treatment market

Detailed Segmentation:

  • Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type:
    • Clotrimazole
    • Nystatin
    • Fluconazole
    • Ketoconazole
    • Terbinafine
    • Terconazole
    • Others
  • Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration:
    • Oral
    • Intravenous
    • Topical
  • Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Acute Vulvovaginal Candidiasis Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
      • By Drug Type:
        • Clotrimazole
        • Nystatin
        • Fluconazole
        • Ketoconazole
        • Terbinafine
        • Terconazole
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Type:
        • Clotrimazole
        • Nystatin
        • Fluconazole
        • Ketoconazole
        • Terbinafine
        • Terconazole
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Type:
        • Clotrimazole
        • Nystatin
        • Fluconazole
        • Ketoconazole
        • Terbinafine
        • Terconazole
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Type:
        • Clotrimazole
        • Nystatin
        • Fluconazole
        • Ketoconazole
        • Terbinafine
        • Terconazole
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Type:
        • Clotrimazole
        • Nystatin
        • Fluconazole
        • Ketoconazole
        • Terbinafine
        • Terconazole
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Type:
        • Clotrimazole
        • Nystatin
        • Fluconazole
        • Ketoconazole
        • Terbinafine
        • Terconazole
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Mycovia Pharmaceuticals, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Scynexis, Inc.
    • Basilea Pharmaceutica Ltd.
    • Astellas Pharma Inc.
    • Grupo Ferrer Internacional, S.A.
    • Pacgen Life Science Corporation
    • NovaDigm Therapeutics, Inc.
    • Cidara Therapeutics, Inc.
    • Amplyx Pharmaceuticals Inc.
    • Pfizer, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Epidemiology
    • Key Developments
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
    • Market Share Analysis
    • Brand Analysis
  4. Acute Vulvovaginal Candidiasis Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
    • During COVID-19 Market Situation
    • Supply Side and Demand Side Analysis
    • Impact of COVID-19 on Acute Vulvovaginal Candidiasis Treatment Market
    • Government Initiatives to Combat COVID-19
  5. Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Clotrimazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Nystatin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Fluconazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Ketoconazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Terbinafine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Terconazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  6. Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Intravenous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Topical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  7. Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  8. Global Acute Vulvovaginal Candidiasis Treatment Market, By Region, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 - 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 - 2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Mycovia Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Scynexis, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Basilea Pharmaceutica Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Astellas Pharma Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Grupo Ferrer Internacional, S.A
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Pacgen Life Science Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • NovaDigm Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Cidara Therapeutics, Inc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Amplyx Pharmaceuticals Inc.,
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 39 market data tables and 29 figures on "Global Acute Vulvovaginal Candidiasis Treatment Market” - Global Forecast to 2027”.

Frequently Asked Questions

The global acute vulvovaginal candidiasis treatment market is expected to exhibit a CAGR of 3.0% during the forecast period (2020-2027).
The global acute vulvovaginal candidiasis treatment market is estimated to be valued at US$ 308.0 million in 2020.
Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc. are some of the prominent players operating in the global acute vulvovaginal candidiasis treatment market.
The global acute vulvovaginal candidiasis treatment market is expected to be valued at US$ 397.8 million in 2027.
Clotrimazole, nystatin, and fluconazole are the most commonly prescribed drug in the global acute vulvovaginal candidiasis treatment market.
North America is the prominent region in the global acute vulvovaginal candidiasis treatment market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner